PriceTargets.com logo

Amgen - AMGN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $333.57
  • Forecasted Upside: 17.62%
  • Number of Analysts: 26
  • Breakdown:
  • 1 Sell Ratings
  • 13 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
$283.61 As of 11/15/2024 01:00 AM ET
▼ -12.32 (-4.16%)

This chart shows the closing price for AMGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amgen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMGN

Analyst Price Target is $333.57
▲ +17.62% Upside Potential
This price target is based on 26 analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $333.57, with a high forecast of $405.00 and a low forecast of $215.00. The average price target represents a 17.62% upside from the last price of $283.61.

This chart shows the closing price for AMGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 26 polled investment analysts is to hold stock in Amgen. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 4 sell ratings
Ratings as of
5/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 3 sell ratings
Ratings as of
8/24/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 2 sell ratings
Ratings as of
11/22/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
2/20/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
8/18/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 12 hold ratings
  • 1 sell ratings
Ratings as of
10/17/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 13 hold ratings
  • 1 sell ratings
Ratings as of
11/16/2024

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 13 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024Wolfe ResearchInitiated CoveragePeer Perform
11/14/2024CitigroupInitiated CoverageNeutral$335.00
11/13/2024CitigroupUpgradeHold
11/12/2024Jefferies Financial GroupReiterated RatingBuy ➝ Buy$380.00 ➝ $380.00
11/12/2024William BlairReiterated RatingOutperform
10/31/2024UBS GroupLower TargetNeutral ➝ Neutral$335.00 ➝ $326.00
10/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$405.00 ➝ $405.00
10/21/2024TD CowenBoost TargetBuy ➝ Buy$381.00 ➝ $383.00
10/17/2024Sanford C. BernsteinInitiated CoverageOutperform$380.00
10/14/2024Truist FinancialDowngradeBuy ➝ Hold$320.00 ➝ $333.00
10/7/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$300.00 ➝ $315.00
9/27/2024Cantor FitzgeraldInitiated CoverageOverweight$405.00
9/26/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$362.00 ➝ $362.00
9/25/2024Robert W. BairdReiterated RatingUnderperform ➝ Underperform$215.00 ➝ $215.00
9/16/2024Dbs BankUpgradeStrong-Buy
8/7/2024TD CowenBoost TargetBuy ➝ Buy$360.00 ➝ $381.00
8/7/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$325.00 ➝ $330.00
8/7/2024Deutsche Bank AktiengesellschaftReiterated RatingHold ➝ Hold$310.00 ➝ $305.00
8/7/2024OppenheimerReiterated RatingOutperform ➝ Outperform$380.00 ➝ $380.00
8/7/2024Jefferies Financial GroupReiterated RatingBuy ➝ Buy$375.00 ➝ $380.00
8/7/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$332.00 ➝ $362.00
8/7/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$320.00 ➝ $335.00
7/11/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$310.00 ➝ $303.00
6/27/2024ArgusBoost TargetBuy ➝ Buy$300.00 ➝ $340.00
6/14/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$328.00 ➝ $332.00
5/9/2024MizuhoBoost TargetNeutral ➝ Neutral$223.00 ➝ $235.00
5/3/2024UBS GroupBoost TargetNeutral ➝ Neutral$284.00 ➝ $307.00
5/3/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$271.00 ➝ $310.00
5/3/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$332.00 ➝ $328.00
5/3/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$336.00 ➝ $355.00
5/3/2024BarclaysUpgradeUnderweight ➝ Equal Weight$230.00 ➝ $300.00
5/3/2024William BlairUpgradeMarket Perform ➝ Outperform
4/17/2024UBS GroupLower TargetNeutral ➝ Neutral$314.00 ➝ $284.00
4/17/2024TD CowenLower TargetBuy ➝ Buy$370.00 ➝ $360.00
4/12/2024Truist FinancialReiterated RatingBuy ➝ Buy$320.00
4/3/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$329.00
3/28/2024Raymond JamesInitiated CoverageMarket Perform
2/7/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$281.00 ➝ $278.00
2/7/2024Leerink PartnrsDowngradeOutperform ➝ Market Perform
2/7/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$303.00 ➝ $329.00
2/7/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$313.00 ➝ $350.00
2/7/2024Leerink PartnersDowngradeOutperform ➝ Market Perform$324.00 ➝ $318.00
2/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$350.00
1/29/2024UBS GroupLower TargetNeutral ➝ Neutral$315.00 ➝ $314.00
12/21/2023Daiwa Capital MarketsUpgradeNeutral ➝ Buy$264.00 ➝ $320.00
12/19/2023BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$286.00 ➝ $326.00
12/12/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$256.00 ➝ $300.00
11/29/2023Truist FinancialReiterated RatingBuy ➝ Buy$320.00
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$240.00
11/2/2023UBS GroupLower TargetNeutral ➝ Neutral$272.00 ➝ $268.00
11/2/2023Truist FinancialUpgradeHold ➝ Buy$260.00 ➝ $320.00
11/1/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$253.00 ➝ $256.00
11/1/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$300.00 ➝ $291.00
10/20/2023OppenheimerBoost TargetOutperform ➝ Outperform$290.00 ➝ $300.00
10/20/2023JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Neutral$270.00
10/17/2023ArgusBoost TargetBuy ➝ Buy$280.00 ➝ $310.00
10/17/2023Morgan StanleyReiterated RatingEqual Weight$300.00
10/12/2023Jefferies Financial GroupReiterated RatingBuy ➝ Buy$310.00
10/12/2023Wells Fargo & CompanyBoost Target$265.00 ➝ $320.00
10/11/2023Leerink PartnrsUpgradeMarket Perform ➝ Outperform
10/11/2023Bank of AmericaInitiated CoverageNeutral$290.00
10/11/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform$267.00 ➝ $318.00
10/9/2023OppenheimerBoost TargetOutperform ➝ Outperform$280.00 ➝ $290.00
10/2/2023BarclaysBoost Target$210.00 ➝ $230.00
9/18/2023ArgusBoost TargetBuy ➝ Buy$260.00 ➝ $280.00
9/6/2023HSBCInitiated CoverageBuy$320.00
9/5/2023Truist FinancialReiterated RatingHold ➝ Hold$260.00
8/14/2023Jefferies Financial GroupBoost TargetBuy ➝ Buy$275.00 ➝ $310.00
8/14/2023MizuhoBoost TargetNeutral ➝ Neutral$214.00 ➝ $223.00
8/4/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$250.00 ➝ $253.00
7/25/2023OppenheimerReiterated RatingOutperform ➝ Outperform$280.00
7/12/2023Credit Suisse GroupLower Target$220.00 ➝ $200.00
7/11/2023BarclaysLower Target$225.00 ➝ $210.00
7/7/2023Jefferies Financial GroupLower Target$325.00 ➝ $275.00
6/26/2023ArgusLower Target$270.00 ➝ $260.00
5/3/2023MizuhoBoost Target$208.00 ➝ $214.00
5/1/2023BarclaysLower Target$227.00 ➝ $225.00
4/28/2023Piper SandlerLower Target$293.00 ➝ $288.00
4/24/2023OppenheimerLower TargetOutperform$292.00 ➝ $290.00
4/14/2023BarclaysLower TargetUnderweight$230.00 ➝ $227.00
3/13/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$275.00 ➝ $265.00
2/13/2023Truist FinancialLower TargetBuy$280.00 ➝ $260.00
2/6/2023ArgusLower Target$300.00 ➝ $270.00
2/2/2023Leerink PartnersLower TargetMarket Perform$282.00 ➝ $267.00
2/2/2023SVB SecuritiesLower Target$282.00 ➝ $267.00
2/1/2023OppenheimerLower TargetOutperform$312.00 ➝ $294.00
2/1/2023Royal Bank of CanadaLower TargetSector Perform$268.00 ➝ $258.00
2/1/2023Wells Fargo & CompanyLower TargetEqual Weight$285.00 ➝ $275.00
2/1/2023BMO Capital MarketsLower TargetMarket Perform$276.00 ➝ $253.00
2/1/2023CowenLower TargetOutperform$307.00 ➝ $289.00
2/1/2023Credit Suisse GroupLower TargetUnderperform$240.00 ➝ $220.00
2/1/2023BarclaysLower TargetUnderweight$240.00 ➝ $230.00
1/19/2023Piper SandlerLower TargetOverweight ➝ Overweight$299.00 ➝ $293.00
1/18/2023BarclaysBoost TargetUnderweight$234.00 ➝ $240.00
1/3/2023Wells Fargo & CompanyBoost TargetEqual Weight$250.00 ➝ $285.00
12/22/2022Leerink PartnersBoost TargetMarket Perform$256.00 ➝ $282.00
12/12/2022Piper SandlerBoost TargetOverweight$297.00 ➝ $299.00
12/6/2022OppenheimerBoost TargetOutperform$300.00 ➝ $310.00
12/5/2022Piper SandlerBoost Target$278.00 ➝ $297.00
11/17/2022Credit Suisse GroupInitiated CoverageUnderperform$240.00
11/15/2022OppenheimerBoost Target$300.00
11/8/2022OppenheimerBoost Target$290.00 ➝ $300.00
11/8/2022Truist FinancialBoost TargetHold ➝ Hold$266.00 ➝ $280.00
11/4/2022Royal Bank of CanadaBoost TargetSector Perform$235.00 ➝ $240.00
11/4/2022Morgan StanleyBoost TargetOverweight$279.00 ➝ $282.00
11/4/2022Piper SandlerBoost TargetOverweight$265.00 ➝ $278.00
10/31/2022BarclaysDowngradeEqual Weight ➝ Underweight$234.00
10/12/2022BarclaysLower TargetEqual Weight$236.00 ➝ $234.00
10/11/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$257.00 ➝ $279.00
10/3/2022OppenheimerReiterated RatingOutperform$290.00
9/14/2022OppenheimerReiterated RatingOutperform ➝ Outperform$290.00
9/13/2022Robert W. BairdReiterated RatingUnderperform$185.00
9/1/2022OppenheimerReiterated RatingOutperform ➝ Outperform$290.00
8/10/2022OppenheimerReiterated RatingBuy ➝ Buy$290.00
8/9/2022Atlantic SecuritiesLower TargetUnderweight$190.00 ➝ $182.00
8/5/2022Piper SandlerBoost TargetOverweight$260.00 ➝ $265.00
8/5/2022Royal Bank of CanadaBoost Target$224.00 ➝ $236.00
7/15/2022Morgan StanleyBoost TargetEqual Weight$239.00 ➝ $253.00
6/24/2022OppenheimerReiterated RatingOutperform ➝ Outperform$290.00
6/1/2022OppenheimerBoost TargetOutperform$285.00 ➝ $290.00
5/23/2022Leerink PartnersInitiated CoverageMarket Perform$256.00
5/10/2022MizuhoBoost Target$202.00 ➝ $208.00
5/3/2022OppenheimerDowngradeOutperform$285.00
4/28/2022BMO Capital MarketsLower Target$263.00 ➝ $243.00
4/28/2022Piper SandlerBoost Target$255.00 ➝ $260.00
4/12/2022Morgan StanleyLower TargetEqual Weight$238.00 ➝ $237.00
4/12/2022BarclaysBoost TargetEqual Weight$233.00 ➝ $236.00
3/1/2022MizuhoBoost Target$194.00 ➝ $202.00
2/9/2022Morgan StanleyBoost TargetEqual Weight$235.00 ➝ $238.00
2/9/2022Jefferies Financial GroupBoost TargetBuy ➝ Buy$266.00 ➝ $280.00
2/9/2022OppenheimerBoost TargetOutperform$272.00 ➝ $285.00
2/9/2022BarclaysBoost TargetEqual Weight$228.00 ➝ $233.00
2/9/2022Wells Fargo & CompanyBoost TargetEqual Weight$210.00 ➝ $250.00
1/5/2022Bank of AmericaDowngradeBuy ➝ Neutral$285.00 ➝ $255.00
12/21/2021Royal Bank of CanadaBoost TargetSector Perform$216.00 ➝ $218.00
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$213.00 ➝ $210.00
12/6/2021The Goldman Sachs GroupInitiated CoverageBuy$258.00
11/22/2021MizuhoLower TargetNeutral$222.00 ➝ $194.00
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$228.00
11/3/2021Royal Bank of CanadaLower TargetSector Perform$217.00 ➝ $216.00
11/3/2021Leerink PartnersLower TargetMarket Perform$234.00 ➝ $216.00
11/3/2021BarclaysLower TargetEqual Weight$230.00 ➝ $228.00
11/1/2021OppenheimerLower TargetOutperform$277.00 ➝ $272.00
10/28/2021Robert W. BairdReiterated RatingSell
10/12/2021Morgan StanleyLower TargetEqual Weight$251.00 ➝ $235.00
9/23/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$220.00
9/19/2021Leerink PartnersInitiated CoverageHold
9/17/2021William BlairReiterated RatingHold
9/10/2021MizuhoInitiated CoverageHold$222.00
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$280.00 ➝ $251.00
8/5/2021Robert W. BairdReiterated RatingSell
8/4/2021Leerink PartnersLower TargetMarket Perform$238.00 ➝ $234.00
7/28/2021Robert W. BairdReiterated RatingSell$185.00
7/16/2021Morgan StanleyBoost TargetOverweight$278.00 ➝ $280.00
6/25/2021MizuhoReiterated RatingHold$200.00
6/7/2021Leerink PartnersBoost TargetMarket Perform$230.00 ➝ $238.00
6/7/2021OppenheimerBoost TargetOutperform$272.00 ➝ $277.00
5/31/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$296.00 ➝ $301.00
5/17/2021OppenheimerReiterated RatingBuy$270.00
5/4/2021Atlantic SecuritiesReiterated RatingNeutral ➝ Underweight$200.00
5/3/2021OppenheimerLower TargetOutperform$275.00 ➝ $265.00
4/29/2021Robert W. BairdReiterated RatingSell
4/29/2021Evercore ISIReiterated RatingBuy
4/28/2021Atlantic SecuritiesDowngradeNeutral ➝ Underweight$200.00
4/28/2021Credit Suisse GroupLower TargetOutperform$265.00 ➝ $259.00
4/28/2021Leerink PartnersLower TargetMarket Perform$267.00 ➝ $230.00
4/28/2021Royal Bank of CanadaLower TargetSector Perform$220.00 ➝ $217.00
4/28/2021JPMorgan Chase & Co.Reiterated RatingNeutral$215.00
4/28/2021The Goldman Sachs GroupReiterated RatingBuy$290.00
4/28/2021BMO Capital MarketsLower TargetOutperform$301.00 ➝ $296.00
4/26/2021Morgan StanleyLower TargetOverweight$281.00 ➝ $278.00
4/19/2021Morgan StanleyBoost TargetOverweight$279.00 ➝ $281.00
4/5/2021OppenheimerBoost Target$266.00 ➝ $275.00
3/5/2021BarclaysLower TargetEqual Weight$242.00 ➝ $230.00
3/5/2021Morgan StanleyBoost TargetOverweight$277.00 ➝ $279.00
3/4/2021JPMorgan Chase & Co.Set TargetNeutral$222.00
3/4/2021The Goldman Sachs GroupSet TargetBuy$277.00
3/1/2021Leerink PartnersBoost TargetMarket Perform$252.00 ➝ $260.00
2/3/2021Morgan StanleyLower TargetOverweight$285.00 ➝ $277.00
2/3/2021Credit Suisse GroupLower TargetOutperform$280.00 ➝ $265.00
2/3/2021Leerink PartnersLower TargetMarket Perform$253.00 ➝ $245.00
2/3/2021Piper SandlerLower TargetOverweight$280.00 ➝ $260.00
2/3/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$280.00 ➝ $295.00
1/31/2021OppenheimerReiterated RatingBuy$266.00
1/19/2021Morgan StanleyBoost TargetOverweight$276.00 ➝ $285.00
1/4/2021Royal Bank of CanadaReiterated RatingNeutral
12/29/2020Daiwa Capital MarketsInitiated CoverageBuy$300.00 ➝ $300.00
12/29/2020Royal Bank of CanadaReiterated RatingNeutral
12/27/2020OppenheimerInitiated CoveragePositive ➝ Buy$274.00 ➝ $266.00
12/27/2020JPMorgan Chase & Co.Reiterated RatingHold
12/23/2020Royal Bank of CanadaReiterated RatingNeutral
12/16/2020Morgan StanleyBoost TargetOverweight$275.00 ➝ $276.00
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy
12/9/2020Leerink PartnersBoost TargetMarket Perform$243.00 ➝ $253.00
12/8/2020Piper SandlerBoost TargetOverweight$270.00 ➝ $280.00
11/16/2020OppenheimerLower TargetOutperform$280.00 ➝ $274.00
11/11/2020OppenheimerInitiated CoveragePositive ➝ Buy$275.00 ➝ $280.00
11/2/2020MizuhoLower TargetNeutral$260.00 ➝ $215.00
10/29/2020Cantor FitzgeraldLower TargetOverweight$279.00 ➝ $278.00
10/29/2020BMO Capital MarketsLower TargetOutperform$308.00 ➝ $304.00
10/29/2020JPMorgan Chase & Co.Lower TargetNeutral$232.00 ➝ $222.00
10/29/2020Leerink PartnersLower TargetMarket Perform$261.00 ➝ $243.00
10/29/2020Bank of AmericaLower TargetBuy$275.00 ➝ $265.00
10/29/2020Morgan StanleyBoost TargetMarket Perform ➝ Overweight$273.00 ➝ $275.00
10/29/2020BarclaysLower TargetEqual Weight$250.00 ➝ $242.00
10/28/2020UBS GroupInitiated CoverageNeutral$232.00
10/27/2020Credit Suisse GroupLower TargetOutperform$286.00 ➝ $284.00
10/26/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$255.00
10/22/2020OppenheimerLower TargetOutperform$280.00 ➝ $275.00
10/15/2020Royal Bank of CanadaReiterated RatingHold$223.00
10/13/2020Morgan StanleyLower TargetOverweight$281.00 ➝ $273.00
10/12/2020Truist FinancialUpgradeHold ➝ Buy
10/9/2020Truist FinancialDowngradeBuy ➝ Hold$251.00
10/9/2020Sanford C. BernsteinDowngradeOutperform ➝ Market Perform
10/6/2020Raymond JamesReiterated RatingOutperform ➝ Market Perform
10/6/2020OppenheimerBoost TargetPositive ➝ Outperform$270.00 ➝ $280.00
9/23/2020William BlairReiterated RatingHold
9/22/2020JPMorgan Chase & Co.Reiterated RatingHold
9/21/2020OppenheimerReiterated RatingBuy$270.00
7/30/2020SunTrust BanksBoost TargetBuy$254.00 ➝ $268.00
7/29/2020Credit Suisse GroupReiterated RatingBuy
7/29/2020Wells Fargo & CompanyBoost TargetEqual Weight ➝ In-Line$237.00 ➝ $247.00
7/29/2020Jefferies Financial GroupBoost TargetBuy$285.00 ➝ $300.00
7/29/2020Royal Bank of CanadaLower TargetSector Perform$236.00 ➝ $223.00
7/29/2020Morgan StanleyLower TargetOverweight$285.00 ➝ $281.00
7/29/2020Leerink PartnersBoost TargetMarket Perform$253.00 ➝ $261.00
7/29/2020Cantor FitzgeraldBoost TargetOverweight$263.00 ➝ $279.00
7/29/2020BarclaysBoost TargetEqual Weight$245.00 ➝ $250.00
7/28/2020Piper SandlerBoost TargetPositive ➝ Overweight$255.00 ➝ $270.00
7/28/2020JPMorgan Chase & Co.Boost TargetNeutral$225.00 ➝ $232.00
7/20/2020OppenheimerBoost TargetOutperform$252.00 ➝ $265.00
7/20/2020Credit Suisse GroupBoost TargetOutperform$252.00 ➝ $290.00
7/15/2020Morgan StanleyBoost TargetOverweight$280.00 ➝ $285.00
6/18/2020JPMorgan Chase & Co.Boost TargetNeutral$219.00 ➝ $225.00
6/2/2020Leerink PartnersBoost TargetMarket Perform$249.00 ➝ $253.00
5/4/2020Cantor FitzgeraldBoost TargetOverweight$255.00 ➝ $263.00
5/1/2020CfraBoost TargetBuy$223.00 ➝ $259.00
5/1/2020Bank of AmericaBoost TargetBuy$250.00 ➝ $265.00
5/1/2020Leerink PartnersBoost TargetMarket Perform$219.00 ➝ $249.00
5/1/2020Morgan StanleyBoost TargetOverweight$267.00 ➝ $280.00
5/1/2020BMO Capital MarketsBoost TargetPositive ➝ Outperform$274.00 ➝ $291.00
5/1/2020Wells Fargo & CompanyBoost TargetEqual Weight$220.00 ➝ $237.00
5/1/2020OppenheimerInitiated CoverageBuy$252.00
4/30/2020MizuhoReiterated RatingHold$215.00
4/30/2020Piper SandlerBoost TargetOverweight$235.00 ➝ $255.00
4/26/2020OppenheimerBoost TargetOutperform$240.00 ➝ $250.00
4/15/2020Morgan StanleyLower TargetOverweight$277.00 ➝ $267.00
4/15/2020GuggenheimInitiated CoverageNeutral$225.00
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$218.00
3/29/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$255.00
3/26/2020OppenheimerLower TargetOutperform$250.00 ➝ $240.00
3/13/2020CfraUpgradeHold ➝ Buy
3/9/2020OppenheimerLower Target$256.00 ➝ $250.00
3/5/2020Bank of AmericaUpgradeNeutral ➝ Buy$245.00 ➝ $250.00
2/27/2020BarclaysInitiated CoverageEqual Weight$235.00
2/6/2020ArgusReiterated RatingBuy$265.00 ➝ $265.00
2/3/2020SunTrust BanksBoost TargetBuy ➝ Buy$254.00 ➝ $265.00
2/2/2020Credit Suisse GroupReiterated RatingBuy$252.00
2/2/2020JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Hold
1/31/2020CfraBoost TargetHold$215.00 ➝ $223.00
1/31/2020CowenReiterated RatingBuy
1/31/2020Robert W. BairdDowngradeNeutral ➝ Underperform$173.00 ➝ $185.00
1/30/2020MizuhoReiterated RatingHold$215.00
1/24/2020JPMorgan Chase & Co.Set TargetNeutral$198.00
1/23/2020CitigroupBoost TargetBuy ➝ In-Line$245.00 ➝ $275.00
1/22/2020UBS GroupBoost TargetNeutral$194.00 ➝ $238.00
1/21/2020OppenheimerBoost Target$250.00 ➝ $260.00
1/21/2020Evercore ISIUpgradeIn-Line ➝ Outperform
1/19/2020JPMorgan Chase & Co.Reiterated RatingHold
1/17/2020Morgan StanleyLower TargetOverweight$280.00 ➝ $277.00
1/14/2020Cantor FitzgeraldReiterated RatingBuy$255.00
1/9/2020BMO Capital MarketsBoost TargetOutperform$240.00 ➝ $275.00
12/23/2019Raymond JamesInitiated CoverageMarket Perform
12/19/2019CowenBoost TargetOutperform$253.00 ➝ $277.00
12/17/2019Morgan StanleyInitiated CoverageOverweight$280.00
12/13/2019Credit Suisse GroupBoost TargetOutperform$235.00 ➝ $250.00
12/9/2019ArgusBoost TargetPositive ➝ Buy$240.00 ➝ $265.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.99 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 43 very positive mentions
  • 20 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
Mentions as of
4/20/2024
  • 62 very positive mentions
  • 51 positive mentions
  • 16 negative mentions
  • 1 very negative mentions
Mentions as of
5/20/2024
  • 48 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
6/19/2024
  • 44 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/19/2024
  • 42 very positive mentions
  • 64 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
8/18/2024
  • 41 very positive mentions
  • 30 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/17/2024
  • 53 very positive mentions
  • 39 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
Mentions as of
10/17/2024
  • 82 very positive mentions
  • 50 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
11/16/2024

Current Sentiment

  • 82 very positive mentions
  • 50 positive mentions
  • 4 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $283.61
Low: $279.62
High: $291.50

50 Day Range

MA: $320.85
Low: $283.61
High: $337.38

52 Week Range

Now: $283.61
Low: $260.52
High: $346.85

Volume

5,325,131 shs

Average Volume

2,323,978 shs

Market Capitalization

$152.45 billion

P/E Ratio

36.31

Dividend Yield

3.17%

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Amgen?

The following Wall Street research analysts have issued reports on Amgen in the last year: Argus, Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Daiwa Capital Markets, Dbs Bank, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for AMGN.

What is the current price target for Amgen?

0 Wall Street analysts have set twelve-month price targets for Amgen in the last year. Their average twelve-month price target is $333.57, suggesting a possible upside of 17.6%. Cantor Fitzgerald has the highest price target set, predicting AMGN will reach $405.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $215.00 for Amgen in the next year.
View the latest price targets for AMGN.

What is the current consensus analyst rating for Amgen?

Amgen currently has 1 sell rating, 13 hold ratings, 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AMGN, but not buy more shares or sell existing shares.
View the latest ratings for AMGN.

What other companies compete with Amgen?

Other companies that are similar to Amgen include Vertex Pharmaceuticals, Gilead Sciences, Regeneron Pharmaceuticals, Seagen and Alnylam Pharmaceuticals. Learn More about companies similar to Amgen.

How do I contact Amgen's investor relations team?

Amgen's physical mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company's listed phone number is (805) 447-1000 and its investor relations email address is [email protected]. The official website for Amgen is www.amgen.com. Learn More about contacing Amgen investor relations.